Siemens completes acquisition of Dotmatics
Acquisition expanding Siemens’ offerings into the life sciences industry
Advertisement
Siemens AG announced today that it has completed the acquisition of Dotmatics, a leading provider of Life Sciences R&D software headquartered in Boston and portfolio company of global software investor Insight Partners, for an enterprise value of $5.1 billion. With the transaction now completed, Dotmatics will form part of Siemens’ Digital Industries Software business, marking a significant expansion of Siemens’ industry-leading Product Lifecycle Management (PLM) portfolio into the rapidly growing and complementary Life Sciences market.
The acquisition of Dotmatics strengthens Siemens’ position as a global leader in AI-powered PLM software and enables Siemens to scale its technologies into Life Sciences to fully address growth opportunities in this market. Dotmatics’ Scientific Intelligence Platform, Luma, and its industry-leading scientific applications enable AI-powered multi-modal drug development, seamless collaboration, and contextualized data creating a connected digital thread across the research-to-production value chain.
“With Dotmatics, we’re building a new era of innovation in Life Sciences. From research through to production – we’re creating a unique, end-to-end digital thread: We combine Dotmatics’ scientific intelligence with our industrial AI technologies and digital twins,” said Roland Busch, President and CEO of Siemens AG. “This will allow us to help our customers accelerate breakthroughs, reduce development cycles, and bring life-saving pharmaceuticals faster and more affordably to the market.”
This transaction expands Siemens’ total addressable market for industrial software by $11 billion and aligns with ‘ONE Tech Company’, the company’s strategic growth program, aimed at accelerating innovation and creating value across industries. Dotmatics is expected to generate more than $300 million in revenue in fiscal year 2025 with an adjusted EBITDA margin above 40 percent, further enhancing Siemens’ growth profile. Dotmatics’ revenue growth and high profitability will be immediately accretive to Siemens’ growth, EBITDA margins and free cash flow, prior to any synergies and special items. Siemens expects substantial revenue synergies: Medium-term revenue synergies expected of around $100 million per year accelerating to over $500 million per year in the long-term.
Other news from the department business & finance
These products might interest you
Image Integrity Checker by Cytiva
Image integrity checker software - authenticate your images for publication
Safeguard and verify your image data with our free software
Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management
ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration
Most read news
More news from our other portals
Last viewed contents
A possible replacement for plastic could lead to stronger, eco-friendly materials for everyday use - It has the potential to become your next disposable water bottle, and so much more
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine - Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
Scientists uncover DNA secrets to bolster corn crop traits - The discovery could enable scientists to use new technologies to improve corn, making it more resilient and productive
Researchers develop process to turn food waste into biodegradable plastic - New process uses bacteria
Turning poison into a source of energy - A research team lhas succeeded in genetically manipulating the microorganism T. kivui to metabolize carbon monoxide
Pigments that can do more - New discovery sheds light on the bacterial use of biomass with potential for biofuels and new antibiotics
Research team achieves breakthrough in environmentally friendly control of invasive pests - Solving a 35-year-old puzzle paves the way for sustainable control of insect pests worldwide
Synthesizing fine chemicals: Technological Advance in Production of Pharmaceuticals
Evotec announces sale of API manufacturing facility to Monacum Partners - New ownership committed to maintaining and growing the business
Ceva Animal Health invests in new 7,000 m² vaccine manufacturing facility to expand global production capacity
Rentschler Biopharma announces largest single investment at its headquarters in Germany - Construction of a new buffer media station in Laupheim
